TBPH - Theravance Biopharma Inc Stock Price, Fair Value and News

9.27USD-0.02 (-0.22%)Delayed as of 20 May 2024, 11:55 am ET

Market Summary

USD9.27-0.02

Delayedas of 20 May 2024, 11:55 am

-0.22%

TBPH Alerts

1 major insider buys recently.

Big jump in Revenue (Y/Y)
Big jump in Earnings (Y/Y)
Losses in recent quarter

TBPH Stock Price

View Fullscreen

TBPH RSI Chart

TBPH Valuation

Market Cap

451.8M

Price/Earnings (Trailing)

-10.09

Price/Sales (Trailing)

8.31

EV/EBITDA

-11.43

Price/Free Cashflow

-26.9

TBPH Price/Sales (Trailing)

TBPH Profitability

EBT Margin

-68.41%

Return on Equity

-21.85%

Return on Assets

-12.06%

Free Cashflow Yield

-3.72%

TBPH Fundamentals

TBPH Revenue

Revenue (TTM)

54.4M

Rev. Growth (Yr)

39.22%

Rev. Growth (Qtr)

-7.58%

TBPH Earnings

Earnings (TTM)

-44.8M

Earnings Growth (Yr)

47.19%

Earnings Growth (Qtr)

-37.06%

Breaking Down TBPH Revenue

52 Week Range

8.2511.35

(Low)(High)

Last 7 days

-1.0%

Last 30 days

-2.4%

Last 90 days

5.6%

Trailing 12 Months

-14.7%

How does TBPH drawdown profile look like?

TBPH Financial Health

Current Ratio

5.74

TBPH Investor Care

Buy Backs (1Y)

15.86%

Diluted EPS (TTM)

-0.86

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	54.4M	0	0	0
2023	51.3M	51.3M	54.5M	0
2022	54.3M	52.4M	52.0M	51.3M
2021	66.3M	64.2M	59.1M	55.3M
2020	87.9M	76.8M	82.6M	71.9M
2019	57.4M	60.1M	59.7M	73.4M
2018	20.6M	40.6M	49.1M	60.4M
2017	33.3M	31.4M	16.6M	15.4M
2016	40.1M	38.5M	46.8M	48.6M
2015	31.1M	35.3M	39.7M	42.1M
2014	1.1M	4.1M	10.4M	11.7M
2013	104.3M	78.5M	52.7M	26.9M
2012	0	0	0	130.1M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Theravance Biopharma Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 08, 2024	broshy eran	acquired	-	-	10,537	-
May 08, 2024	o'connor donal	acquired	-	-	10,537	-
May 08, 2024	mitchell dean j	acquired	-	-	10,537	-
May 08, 2024	smaldone alsup laurie	acquired	-	-	10,537	-
May 08, 2024	grant jeremy t	acquired	-	-	10,537	-
May 08, 2024	gray susannah	acquired	-	-	10,537	-
May 08, 2024	pakianathan deepika	acquired	-	-	10,537	-
May 01, 2024	samaha eli	bought	13,117,300	8.75	1,499,120	-
Apr 02, 2024	farnum rhonda	acquired	-	-	37,500	svp, comm & medical affairs
Apr 02, 2024	winningham rick e	acquired	-	-	300,000	chief executive officer

Which funds bought or sold TBPH recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-17.1	-176,424	344,932	-%
May 16, 2024	JANE STREET GROUP, LLC	reduced	-90.95	-3,874,390	301,464	-%
May 15, 2024	QUADRANT CAPITAL GROUP LLC	added	161	3,486	6,701	-%
May 15, 2024	MARSHALL WACE, LLP	new	-	1,453,800	1,453,800	-%
May 15, 2024	Park West Asset Management LLC	added	28.57	263,752	10,379,800	0.74%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-98.29	-258,704	3,570	-%
May 15, 2024	PDT Partners, LLC	added	104	231,523	595,958	0.06%
May 15, 2024	Newtyn Management, LLC	reduced	-13.48	-6,609,950	14,746,100	2.94%
May 15, 2024	Cubist Systematic Strategies, LLC	new	-	52,331	52,331	-%
May 15, 2024	Engineers Gate Manager LP	reduced	-52.28	-173,833	106,931	-%

Are Funds Buying or Selling TBPH?

Are funds buying TBPH calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own TBPH

No. of Funds

Unveiling Theravance Biopharma Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
May 03, 2024	madison avenue partners, lp	17.5%	8,511,350	SC 13G/A
Mar 05, 2024	weiss asset management lp	15.5%	7,457,060	SC 13D/A
Feb 14, 2024	irenic capital management lp	5.5%	2,760,948	SC 13G
Feb 13, 2024	vanguard group inc	7.01%	3,489,262	SC 13G/A
Feb 08, 2024	blackrock inc.	9.2%	4,584,596	SC 13G/A
Aug 14, 2023	weiss asset management lp	14.%	7,457,060	SC 13D/A
Jul 10, 2023	baupost group llc/ma	12.84%	7,419,226	SC 13G/A
Apr 12, 2023	weiss asset management lp	11.%	7,457,060	SC 13D
Feb 14, 2023	orbimed advisors llc	0%	0	SC 13G/A
Feb 14, 2023	madison avenue partners, lp	10.4%	7,012,226	SC 13G/A

Recent SEC filings of Theravance Biopharma Inc

View All Filings

Date Filed	Form Type	Document
May 17, 2024	4	Insider Trading
May 15, 2024	10-Q	Quarterly Report
May 13, 2024	8-K	Current Report
May 10, 2024	4	Insider Trading
May 10, 2024	4	Insider Trading
May 10, 2024	4	Insider Trading
May 10, 2024	4	Insider Trading
May 10, 2024	4	Insider Trading
May 10, 2024	4	Insider Trading
May 10, 2024	4	Insider Trading

Peers (Alternatives to Theravance Biopharma Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.48%	6.04%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.81%	-21.31%	-56.91	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.27%	-15.91%	71.68	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.31%	-10.26%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.46%	115.24%	-10.3	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.80%	-0.43%	-12.27	14.48	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-13.96%	-36.25%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Theravance Biopharma Inc News

Latest updates

Theravance Biopharma Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-7.6%	14,503,000	15,693,000	13,749,000	10,417,000	14,649,000	12,451,000	11,750,500	11,050,000	13,196,000	14,946,000	13,194,000	12,914,000	14,257,000	18,730,000	18,257,000	15,008,000	19,862,000	29,499,000	12,427,000	26,150,000	5,338,000
Operating Expenses	5.1%	25,710,000	24,453,000	29,872,000	35,329,000	32,081,000	21,595,000	-	37,929,000	51,698,000	71,113,000	66,809,000	77,024,000	98,149,000	95,220,000	94,872,000	87,184,000	92,338,000	100,071,000	77,628,000	68,626,000	79,004,000
S&GA Expenses	3.7%	16,742,000	16,142,000	19,278,000	19,183,000	16,732,000	16,277,000	-15,890,000	16,222,000	17,842,000	21,516,000	21,299,000	25,931,000	30,550,000	29,925,000	27,501,000	24,780,000	26,325,000	33,046,000	25,622,000	22,227,000	25,186,000
R&D Expenses	7.9%	8,968,000	8,311,000	9,425,000	14,572,000	15,348,000	9,867,000	-	14,924,000	23,253,000	31,226,000	43,739,000	51,093,000	67,599,000	65,165,000	67,371,000	62,404,000	66,013,000	67,025,000	52,006,000	46,399,000	53,818,000
EBITDA Margin	33.9%	-0.64	-0.97	-1.18	-1.31	-1.62	-2.79	-3.53	-3.51	-3.76	-4.23	-4.52	-4.29	-4.32	-	-	-	-	-	-	-	-
Interest Expenses	3.3%	629,000	609,000	568,000	550,000	550,000	1,545,000	-	2,137,000	2,137,000	-7,468,500	2,136,000	11,612,000	11,873,000	-24,358,000	11,573,000	11,391,000	9,941,000	8,035,000	8,068,000	7,901,000	7,858,000
Income Taxes	-7.1%	1,300,000	1,400,000	1,500,000	-395,000	-3,000	-507,000	-	-5,000	524,000	1,756,000	-7,000	-220,000	227,000	-8,799,000	93,000	39,000	147,000	49,000	-5,552,000	201,000	80,000
Earnings Before Taxes	-37.2%	-10,402,000	-7,583,000	-14,187,000	-22,483,000	-14,259,000	-16,023,000	-	-22,798,000	-39,735,000	-67,597,000	-55,917,000	-52,625,000	-79,452,000	-84,039,000	-73,550,000	-62,848,000	-82,906,000	-65,557,000	-63,983,000	-39,637,000	-72,500,000
EBT Margin	36.3%	-0.68	-1.07	-1.31	-1.47	-1.81	-2.83	-3.58	-3.55	-3.98	-4.62	-4.60	-4.51	-4.53	-	-	-	-	-	-	-	-
Net Income	-30.3%	-11,664,000	-8,950,000	-15,645,000	-22,088,000	-10,362,000	916,631,000	31,629,000	-8,191,000	-25,946,000	-32,034,000	-35,308,000	-52,405,000	-79,679,000	-58,434,000	-73,643,000	-62,887,000	-83,053,000	-65,606,000	-58,431,000	-39,838,000	-72,580,000
Net Income Margin	21.3%	-0.82	-1.05	16.94	17.85	18.11	17.68	-0.66	-1.94	-2.69	-3.61	-3.82	-4.12	-4.15	-	-	-	-	-	-	-	-
Free Cashflow	67.3%	-1,022,000	-3,124,000	-13,074,000	-11,859,000	-124,693,000	-22,775,000	-15,368,000	-15,368,000	-26,707,000	-43,072,000	-46,084,000	-50,751,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2
Assets	-2.8%	371	382	414	447	539	607	763	72.00	361	355	375	403	429	375	469	512	564	605	409	445	492
Current Assets	-6.9%	124	134	162	192	261	353	512	-	155	205	250	297	333	293	393	451	498	534	37.00	356	426
Cash Equivalents	38.3%	55.00	40.00	72.00	106	188	298	419	29.00	87.00	94.00	91.00	121	205	114	81.00	93.00	105	333	59.00	102	178
Net PPE	-3.9%	9.00	9.00	9.00	10.00	12.00	12.00	12.00	-	13.00	13.00	14.00	16.00	17.00	17.00	16.00	15.00	14.00	14.00	13.00	12.00	13.00
Current Liabilities	-12.5%	22.00	25.00	25.00	25.00	26.00	29.00	142	-	33.00	44.00	59.00	66.00	67.00	86.00	124	104	107	98.00	3.00	109	110
Shareholder's Equity	-3.8%	205	213	246	280	371	442	481	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-1.3%	-920	-909	-900	-891	-876	-853	-843	-	-1,760	-1,751	-1,726	-1,694	-1,658	-1,606	-1,526	-1,468	-1,394	-1,331	-1,248	-1,182	-1,124
Additional Paid-In Capital	0.3%	1,126	1,122	1,147	1,172	1,247	1,296	1,324	-	1,410	1,401	1,387	1,370	1,358	1,233	1,223	1,207	1,192	1,173	1,025	1,000	987
Shares Outstanding	1.0%	49.00	48.00	51.00	54.00	61.00	65.00	76.00	76.00	76.00	75.00	74.00	74.00	65.00	-	-	-	-	-	-	-	-
Float	-	-	-	-	459	-	-	-	-	677	-	-	-	882	-	-	-	1,280	-	-	-	893

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-19.7%	-1.02	-0.85	-2.49	-12.44	-11.22	-124	-22.14	-14.73	-26.07	-42.43	-45.45	-50.11	-69.86	-64.92	-77.03	-53.35	-55.10	-64.35	-44.62	-48.03	-81.19
Share Based Compensation	-10.2%	5.00	6.00	6.00	6.00	7.00	7.00	9.00	10.00	15.00	17.00	14.00	15.00	16.00	16.00	16.00	17.00	15.00	24.00	13.00	11.00	12.00
Cashflow From Investing	2615.2%	17.00	-0.68	-0.02	11.00	-43.05	39.00	1,075	8.00	32.00	11.00	-35.79	36.00	114	52.00	67.00	-176	68.00	14.00	-23.66	-1.30	-72.16
Cashflow From Financing	94.4%	-1.72	-30.61	-31.40	-80.68	-56.24	-35.47	-722	0.00	-1.45	0.00	-2.29	105	-11.29	1.00	-0.96	2.00	261	-1.54	-0.13	4.00	-1.43
Buy Backs	-98.5%	0.00	30.00	31.00	81.00	55.00	-	94.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

TBPH Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
shares in Thousands, $ in Thousands

3 Months Ended

Mar. 31, 2024

Mar. 31, 2023

Revenue:

Total revenue

$ 14,503

$ 10,417

Expenses:

Research and development

^[1]

8,968

14,572

Selling, general and administrative

^[1]

16,742

19,183

Restructuring and related expenses

^[1]

1,574

Total expenses

25,710

35,329

Loss from operations

(11,207)

(24,912)

Interest expense (non-cash)

(629)

(550)

Interest income and other income (expense), net

1,434

2,979

Loss before income taxes

(10,402)

(22,483)

Provision for income tax expense (benefit)

1,262

(395)

Net loss

(11,664)

(22,088)

Other comprehensive loss:

Net unrealized gain on available-for-sale investments

Total comprehensive loss

$ (11,640)

$ (22,022)

Net loss per share:

Net loss - basic (in dollars per share)

$ (0.24)

$ (0.35)

Net loss - diluted (in dollars per share)

$ (0.24)

$ (0.35)

Shares used to compute net income (loss) per share - basic

48,283

62,934

Shares used to compute net income (loss) per share - diluted

48,283

62,934

Viatris collaboration agreement

Revenue:

Total revenue

$ 14,503

$ 10,411

Collaboration revenue

Revenue:

Total revenue

$ 6

[1]	Amounts include share-based compensation expense as follows:

TBPH Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 53,835	$ 39,545
Short-term marketable securities	46,140	62,881
Receivables from collaborative arrangements	14,664	17,474
Prepaid clinical and development services	2,086	2,038
Other prepaid and current assets	7,569	11,603
Total current assets	124,294	133,541
Property and equipment, net	8,717	9,068
Operating lease assets	35,364	36,287
Future contingent milestone and royalty assets	194,200	194,200
Restricted cash	836	836
Other assets	7,896	8,067
Total assets	371,307	381,999
Current liabilities:
Accounts payable	1,686	1,524
Accrued personnel-related expenses	4,475	6,443
Accrued clinical and development expenses	1,399	2,246
Accrued general and administrative expenses	2,476	2,900
Operating lease liabilities	4,063	3,923
Tenant improvement payable to subleasee	6,490	6,490
Other accrued liabilities	1,073	1,241
Total current liabilities	21,662	24,767
Long-term operating lease liabilities	43,840	45,236
Future royalty payment contingency	28,417	27,788
Unrecognized tax benefits	67,075	65,294
Other long-term liabilities	5,445	5,919
Commitments and contingencies (Note 10)
Shareholders' Equity
Preferred shares, $0.00001 par value: 230 shares authorized, no shares issued or outstanding
Ordinary shares, $0.00001 par value per share: 200,000 shares authorized; 48,566 and 48,091 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively
Additional paid-in capital	1,125,677	1,122,164
Accumulated other comprehensive loss	(41)	(65)
Accumulated deficit	(920,768)	(909,104)
Total shareholders' equity	204,868	212,995
Total liabilities and shareholders' equity	$ 371,307	$ 381,999

About Theravance Biopharma Inc

Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has licensing and collaboration agreements with Pfizer Inc. for its preclinical skin-selective pan-JAK inhibitor program, as well as Viatris Inc. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.

CEO	Mr. Rick E. Winningham M.B.A.
WEBSITE	theravance.com
INDUSTRY	Biotechnology
EMPLOYEES	111

Theravance Biopharma Inc Frequently Asked Questions

What is the ticker symbol for Theravance Biopharma Inc? What does TBPH stand for in stocks?

TBPH is the stock ticker symbol of Theravance Biopharma Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Theravance Biopharma Inc (TBPH)?

As of Fri May 17 2024, market cap of Theravance Biopharma Inc is 451.8 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TBPH stock?

You can check TBPH's fair value in chart for subscribers.

What is the fair value of TBPH stock?

You can check TBPH's fair value in chart for subscribers. The fair value of Theravance Biopharma Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Theravance Biopharma Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TBPH so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Theravance Biopharma Inc a good stock to buy?

The fair value guage provides a quick view whether TBPH is over valued or under valued. Whether Theravance Biopharma Inc is cheap or expensive depends on the assumptions which impact Theravance Biopharma Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TBPH.

What is Theravance Biopharma Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, TBPH's PE ratio (Price to Earnings) is -10.09 and Price to Sales (PS) ratio is 8.31. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TBPH PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Theravance Biopharma Inc's stock?

In the past 10 years, Theravance Biopharma Inc has provided -0.081 (multiply by 100 for percentage) rate of return.